Sugi Predict

Sugi Predict / Compounds / SCHEMBL2190227

SCHEMBL2190227

SCHEMBL2190227

Cc1cccc(NC(=O)CCl)n1

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.66
▸ NPC1 O15118 5/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ GRM5 P41594 2/20 0.63
▸ KMT2A Q03164 4/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ POLB P06746 1/20 0.58
▸ MAPT P10636 2/20 0.57
▸ MEN1 O00255 2/20 0.56
▸ TSHR P16473 1/20 0.56
▸ GBA1 P04062 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30440441 1.00 RAB9A (0.66) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL13841479 0.84 RAB9A (0.68) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL8240316 0.84 RAB9A (0.71) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL20095383 0.84 RAB9A (0.58) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL9885823 0.83 ALDH1A1 (0.67) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL10665125 0.83 RAB9A (0.66) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL2578961 0.81 ALDH1A1 (0.71) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL13026590 0.80 SMN1; SMN2 (0.81) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL31725239 0.80 RAB9A (0.78) RAB9ANPC1SMN1; SMN2GRM5KMT2A
SCHEMBL14353530 0.80 RAB9A (1.00) RAB9ANPC1SMN1; SMN2GRM5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 — — US disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 — — US disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 — — US disclosed
EP-4249475-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2023-09-27 — — EP disclosed
CN-116438167-A Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof 美迪福伦DBT有限公司 2023-07-14 — — CN disclosed
WO-2022108377-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF (주) 메디프론디비티 2022-05-27 — — WO disclosed
EP-3193880-B1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL LILLY CO ELI (US) 2020-03-25 — — EP disclosed
US-10519158-B2 Inhibiting the transient receptor potential A1 ion channel ELI LILLY AND COMPANY (US) 2019-12-31 — — US disclosed
US-20190330212-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2019-10-31 — — US disclosed
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel HYDRA BIOSCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-20130030001-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2013-01-31 — — US disclosed
US-20130030001-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2013-01-31 — — US disclosed
US-8329729-B2 Quinuclidine derivatives as muscarinic M3 receptor antagonists ASTRAZENECA AB (SE) 2012-12-11 — — US disclosed
US-8329729-B2 Quinuclidine derivatives as muscarinic M3 receptor antagonists ASTRAZENECA AB (SE) 2012-12-11 — — US disclosed
US-20110172237-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS ASTRAZENECA UK LIMITED (GB) 2011-07-14 — — US disclosed
US-20110172237-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS ASTRAZENECA UK LIMITED (GB) 2011-07-14 — — US disclosed
CN-102089304-A Quinuclidine derivatives as M3 muscarinic receptor antagonists ASTRAZENECA AB 2011-06-08 — — CN disclosed
WO-2009138707-A9 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2010-01-28 — — WO disclosed
WO-2009138707-A9 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2010-01-28 — — WO disclosed
WO-2009138707-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2009-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10519158-B2 Inhibiting the transient receptor potential A1 ion channel TRPV1, TRPA1, TRPV2 RAB9A 1779/4885NPC1 484/4885SMN1; SMN2 905/4885
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel TRPV1, TRPA1, TRPV2 RAB9A 1779/4885NPC1 484/4885SMN1; SMN2 905/4885
US-20110172237-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS CHRM3, CHRM2, CHRM1 RAB9A 1161/4885NPC1 1785/4885SMN1; SMN2 4555/4885
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF OGA, OGT, ENGASE RAB9A 2825/4885NPC1 3307/4885SMN1; SMN2 4435/4885
US-20130030001-A1 QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS CHRM3, CHRM2, CHRM5 RAB9A 1456/4885NPC1 2038/4885SMN1; SMN2 4330/4885
US-20190330212-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL TRPV1, TRPA1, TRPV2 RAB9A 1779/4885NPC1 484/4885SMN1; SMN2 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.